Salvage Therapy with Second-Generation Inhibitors for FLT3 Mutated Acute Myeloid Leukemia: A Real-World Study by the CETLAM and PETHEMA GroupsSusana Vives, Pau Montesinos, David Quintela et al.|Cancers|2024Cited by 4
Long-term benefits of autologous stem cell transplantation versus intensive chemotherapy consolidation for acute myeloid leukemia patients: A propensity score matching analysis from the PETHEMA AML registryAna Alfonso Piérola, Cristina Gil, Pilar Martínez‐Sánchez et al.|Leukemia|2025Cited by 1